Consistent with the role of ROS in inflammatory hypoxia, most CGD patients manifest inflammatory bowel disease–like symptoms (Campbell & Colgan, 2019), and pharmacological stabilization of HIF-1α within the mucosa protected CGD mice from severe colitis (Campbell et al, 2014). The gene discussed is HIF1A; the disease is colitis.